Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Equity Ratio (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Equity Ratio for 14 consecutive years, with 0.77 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 4.23% to 0.77 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.77 through Dec 2025, down 4.23% year-over-year, with the annual reading at 0.77 for FY2025, 4.23% down from the prior year.
  • Equity Ratio hit 0.77 in Q4 2025 for Corcept Therapeutics, up from 0.77 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.92 in Q1 2021 to a low of 0.77 in Q3 2025.
  • Historically, Equity Ratio has averaged 0.84 across 5 years, with a median of 0.83 in 2024.
  • Biggest five-year swings in Equity Ratio: decreased 12.45% in 2023 and later increased 4.81% in 2024.
  • Year by year, Equity Ratio stood at 0.89 in 2021, then dropped by 3.01% to 0.86 in 2022, then fell by 5.22% to 0.82 in 2023, then fell by 0.83% to 0.81 in 2024, then dropped by 4.23% to 0.77 in 2025.
  • Business Quant data shows Equity Ratio for CORT at 0.77 in Q4 2025, 0.77 in Q3 2025, and 0.79 in Q2 2025.